Supplementary Data S1 from <i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects | Publicación